Essential Hypertension
Conditions
Keywords
ALERT, MSSBP, MSDBP
Brief summary
To determine the efficacy of valsartan/amlodipine 80/5 mg once daily dose is reducing mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) after 8 weeks of therapy.
Detailed description
Avsar in tablet form which contains two antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland International studies are available concerning the single pill combination therapy used in Blood pressure reduction. To determine the clinical significance of single pill combination, conducted multi center real life study i.e.; ALERT Trial in our local population. Through this study, observed the effect of single pill combination on BP reduction and adverse events in health care settings. Antihypertensive drugs use in a single pill combination may further enhance BP control by reducing pill burden and improve patient compliance.
Interventions
DRUGValsartan, Amlodipine -
Valsartan is a non-peptide, orally active, and specific angiotensin II receptor blocker acting on the AT1 receptor subtype used as an antihypertensive agent. Amlodipine besylate is a dihydropyridine long-acting calcium channel blocker.
Sponsors
PharmEvo Pvt Ltd
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patient whose BP is \>139/89mmHg and on monotherapy with minimum last 30 days * Male or female aged (18 years - 70 Years) * Signed informed consent
Exclusion criteria
* Secondary Hypertension * Pregnant or Lactating mother * Hypersensitivity to any active ingredient * Peripheral artery disease * Hepatic disease or biliary tract obstruction * Chronic kidney disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of valsartan/amlodipine 80/5 mg once daily dose is reducing mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure after 8 weeks of therapy. | 8 weeks | To determine the efficacy of valsartan/amlodipine 80/5 mg once daily dose is reducing mean sitting systolic blood pressure (MSSBP) after 8 weeks of therapy. \[Designated as safety issue: No\] |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measure percentage of participant with blood pressure change of <139/89 mmHg at the end of 8 week | 8 weeks | To measure percentage of participant with blood pressure change of \<139/89 mmHg at the end of 8 week \[Designated as safety issue: No\] |
| Participants experiencing adverse effect after taking single pill combination | 8 weeks | Proportion of participants experiencing adverse effect after taking single pill combination \[Designated as safety issue: Yes\] |
Countries
Pakistan
Outcome results
None listed